Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$5.77
+2.9%
$6.49
$5.20
$15.60
$10.75M0.9211,177 shs23,736 shs
CZX
Canada Zinc Metals
C$0.31
+∞
C$0.31
C$0.22
C$0.39
C$51.69MN/A238,645 shs118,500 shs
First Capital Realty Inc. stock logo
FCR
First Capital Realty
C$0.00
C$18.60
C$22.79
N/AN/A468,009 shs3.04 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
+2.85%+3.04%-6.03%-24.67%-61.53%
CZX
Canada Zinc Metals
0.00%0.00%0.00%0.00%0.00%
First Capital Realty Inc. stock logo
FCR
First Capital Realty
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
3.4716 of 5 stars
3.23.00.00.03.33.31.3
CZX
Canada Zinc Metals
N/AN/AN/AN/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
2.33
Hold$50.00766.55% Upside
CZX
Canada Zinc Metals
0.00
N/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
4.00
Strong BuyN/AN/A

Current Analyst Ratings Breakdown

Latest AVW, BOLT, CZX, and FCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$80.00
5/13/2025
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$25.00 ➝ $20.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$7.69M1.44N/AN/A$29.89 per share0.19
CZX
Canada Zinc Metals
N/AN/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$63.12M-$33.40N/AN/AN/A-665.56%-94.51%-59.07%8/12/2025 (Estimated)
CZX
Canada Zinc Metals
N/AN/A0.00N/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest AVW, BOLT, CZX, and FCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$6.80-$5.80+$1.00-$0.29$0.77 million$1.22 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
N/AN/AN/AN/AN/A
CZX
Canada Zinc Metals
N/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
0.48
3.13
3.13
CZX
Canada Zinc Metals
N/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
86.70%
CZX
Canada Zinc Metals
N/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/A

Insider Ownership

CompanyInsider Ownership
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
30.90%
CZX
Canada Zinc Metals
N/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
901.92 million1.33 millionNot Optionable
CZX
Canada Zinc Metals
147,000166.73 millionN/ANot Optionable
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/ANot Optionable

Recent News About These Companies

CEO buying at First Capital REIT (FCR)
RBC Capital Keeps Their Buy Rating on First Capital Realty (FCR.UN)
First Capital REIT reports “strong” financial results
Learn to Evaluate (FCR.UN) using the Charts
3 Canadian Dividend Stocks to Load Up on Now
First Capital REIT Announces October 2024 Distribution
Dream Unlimited, Scotiabank, EQB at 52-Week Highs on News

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bolt Biotherapeutics stock logo

Bolt Biotherapeutics NASDAQ:BOLT

$5.77 +0.16 (+2.85%)
As of 06/30/2025 03:58 PM Eastern

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Canada Zinc Metals CVE:CZX

C$0.31 +0.31 (+∞)
As of 05/4/2018

Canada Zinc Metals Corp. explores for and evaluates mineral resource properties in Canada. The company primarily explores for zinc-lead-silver base metals deposits. Its flagship property is the Akie property that consists of 46 mineral claims, which cover approximately 116 square kilometers, located in the Paleozoic Selwyn Basin, British Columbia. The company was formerly known as Mantle Resources Inc. and changed its name to Canada Zinc Metals Corp. in September 2008. Canada Zinc Metals Corp. was incorporated in 1988 and is headquartered in Vancouver, Canada.